7 completed, 1 unknown. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 7, Unknown 1 |
Follow Hypophosphatemia, Familial: new trials by email Literature Review of Hypophosphatemia, Familial trials Research Report on Hypophosphatemia, Familial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prevention of Spontaneous Dental Abscesses in Children With X-linked Hypophosphatemia : a RCT adhesive system, fluoride varnish, flowable composite - X-linked Hypophosphatemia (XLH) | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 60 | 2021-06-01 | 2021-05-05 |
| Anti-FGF23 (Burosumab) in Adult Patients With XLH Burosumab - X-linked Hypophosphatemia | Phase 3 | Completed | Wuerzburg University Hospital | 36 | 2021-01-07 | 2023-05-03 |
| Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH Burosumab - X-linked Hypophosphatemia | Phase 3 | Completed | Kyowa Kirin Pharmaceutical Development Ltd | 35 | 2019-03-07 | 2022-05-20 |
| A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia KRN23 - X-linked Hypophosphatemic Rickets/Osteomalacia | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 16 | 2017-07-06 | 2022-09-06 |
| Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH burosumab, Oral Phosphate Supplement, active vitamin D - X-Linked Hypophosphatemia | Phase 3 | Completed | Kyowa Kirin, Inc. | 61 | 2016-09-08 | 2024-08-29 |
| Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH) burosumab - X-linked Hypophosphatemia | Phase 3 | Completed | Kyowa Kirin, Inc. | 14 | 2015-12-23 | 2024-06-18 |
| Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH) burosumab, Placebo - X-linked Hypophosphatemia | Phase 3 | Completed | Kyowa Kirin, Inc. | 134 | 2015-10-22 | 2024-06-18 |
| Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets Paricalcitol, Placebo - Hypophosphatemia, Familial, Hyperparathyroidism | Phase 3 | Completed | Yale University | 33 | 2007-01-01 | 2020-03-17 |
Familial Hypophosphatemic Rickets (8) · Hyperparathyroidism (1) · Hypophosphatemia (1) · Osteomalacia (1) · Rickets (1) · Rickets, Hypophosphatemic (1)
Avitaminosis (8) · Bone Diseases (8) · Bone Diseases, Metabolic (8) · Calcium Metabolism Disorders (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Deficiency Diseases (8) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Genetic Diseases, Inborn (8) · Kidney Diseases (8) · Male Urogenital Diseases (8) · Malnutrition (8) · Metabolic Diseases (8) · Metabolism, Inborn Errors (8) · Metal Metabolism, Inborn Errors (8)
burosumab (6) · flowable hybrid composite (1) · paricalcitol (1)
Kyowa Kirin, Inc. (3) · Assistance Publique - Hôpitaux de Paris (1) · Kyowa Kirin Co., Ltd. (1) · Kyowa Kirin Pharmaceutical Development Ltd (1) · Wuerzburg University Hospital (1) · Yale University (1)
Japan (4) · United States (4) · France (3) · South Korea (3) · United Kingdom (3) · Canada (2) · Ireland (2) · Italy (2) · Australia (1) · Denmark (1) · Germany (1) · Sweden (1)
Lothar Seefried, MD (1) · Peter Kamenicky (1) · Thomas O. Carpenter, MD (1)
PMID 39151033, PMID 36854566, PMID 25029424, PMID 29947083, PMID 31104833, PMID 31165191, PMID 32721016, PMID 33484279, PMID 34548383, PMID 35533340, PMID 35775373, PMID 35927518, PMID 36719566, PMID 37084401
2014 (1), P50AR054086 (1)